UPDATE: Stifel Reiterates Buy Rating, Raises PT on HealthSouth Corp. as Second Quarter Easily Exceeds Projection

In a report published Tuesday, Stifel analyst Robert Mains reiterated a Buy rating on HealthSouth Corp. HLS, and raised the price target from $38.00 to $41.00. In the report, Stifel noted, “HealthSouth reported second quarter earnings well ahead of our estimate. The company reported income from continuing operations per share (its EPS proxy) of $0.81, beating our $0.65 estimate. Excluding an accounting gain, income from continuing operations per share were $0.54 compared to our at-consensus $0.48 estimate. We are raising our earnings estimate and target price, as the company also increased its guidance.” HealthSouth Corp. closed on Monday at $37.64.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsRobert MainsStifel
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!